Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

December 4, 2020

Study Completion Date

December 4, 2020

Conditions
Covid19
Interventions
DRUG

UNI911 inhalation 1% and intranasal spray 1%

Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.

DRUG

Placebo

The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.

Trial Locations (1)

Unknown

DanTrials ApS, Copenhagen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UNION therapeutics

INDUSTRY

NCT04576312 - Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers | Biotech Hunter | Biotech Hunter